Budesonide/Mesalazine

布地奈德/美沙拉嗪

Report date: 2025/11/27 15:17:30

Base Information

Drug NameBudesonide/Mesalazine
Drug Alias NameMesalazine/Budesonide布地奈德+美沙拉嗪美沙拉嗪/布地奈德Mesalazine+Budesonide美沙拉嗪+布地奈德 +[6] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionGlucocorticoid receptor agonistsProtein phosphatase 2A inhibitors
TargetsGlucocorticoid receptorProtein phosphatase 2A
Therapy Area/IndicationsUlcerative proctitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes MesalazineBudesonide
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDr. Falk Pharma GmbH
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDr. Falk Pharma GmbH
Active IndicationsN/A
Inactive IndicationsUlcerative proctitis

Other Information

ATC CodeN/A
Related LinksN/A